Evista, also called raloxifene, is a medication that's used to reduce the risk of invasive breast cancer in post-menopausal women. It's also used to reduce the risk of spinal fractures related to ...

Eli Lilly ($LLY) is staring down the barrel of its Evista patent expiration. And Tuesday, Teva Pharmaceutical Industries ($TEVA) won FDA approval to load the bullet ...

The STAR (Study of Tamoxifen and Raloxifene) trial, one of the largest breast cancer prevention trials ever conducted, showed that five years of Evista is as effective as tamoxifen in lowering risk of ...

INDIANAPOLIS, Aug. 9, 2011 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that data on EVISTA® (raloxifene HCl tablets) therapy for more than three years was published online in ...

Eli Lilly got a bit of vindication on Tuesday after a judge placed a 10-day restraining order on generic drugmaker Teva Pharmaceuticals, which tried to violate Lilly's patents. The two drugmakers are ...

WASHINGTON, Sept 1 (Reuters) - Eli Lilly & Co won a patent battle protecting its osteoporosis drug Evista on Wednesday, as an appeals court declined to toss out a permanent injunction preventing ...

The aromatase inhibitor Femara is next up in new Evista study for breast cancer prevention. Landmark data from the STAR trial comparing tamoxifen and Evista® (raloxifene) showed Evista was comparable ...

Researchers say a drug prescribed for osteoporosis may protect against endometrial cancer. Women who took Evista "had about half the risk of endometrial cancer than those not using the drug," says ...